The American laboratory Pfizer invoiced 25.7 billion dollars in the first quarter of 2022, an increase of 77% compared to the same period last year, largely thanks to the sales of its anticovid vaccine.
The firm also maintained the sales forecast for its Paxlovid anticovid pill of 22,000 million dollars in the year.
Meanwhile, Pfizer revised down its full-year profit estimate, mainly due to a change in accounting standards.
Sending Data…
